Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Onyx Pharmaceuticals on Key Endorsement

Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Onyx Pharmaceuticals (NASDAQ: ONXX).

Morgan Stanley noted, “Addition of Kyprolis to National Comprehensive Cancer Network or NCCN treatment guidelines for newly diagnosed myeloma patients undergoing stem cell transplant is an expected positive. Front line use is largely upside to MSe/consensus and should allay concerns about competitive pressures from Celgene's Pomalyst. Moreover, guideline inclusion will ease frontline reimbursement and create an additional source of growth in the coming quarters.”

Onyx Pharmaceuticals closed on Friday at $85.65.

Latest Ratings for ONXX

DateFirmActionFromTo
Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ONXX)

Around the Web, We're Loving...

Get Benzinga's Newsletters